Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.

@article{Asn2014BacillusC,
  title={Bacillus Calmette-Gu{\'e}rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature.},
  author={Mar{\'i}a Asunci{\'o}n P{\'e}rez-Jacoiste As{\'i}n and Mario Fern{\'a}ndez-Ruiz and Francisco L{\'o}pez-Medrano and Carlos Lumbreras and Angel Tejido and Rafael San Juan and Ana Arr{\'e}bola-Pajares and Manuel Lizasoa{\'i}n and Santiago Prieto and Jose Aguado},
  journal={Medicine},
  year={2014},
  volume={93 17},
  pages={236-54}
}
Bacillus Calmette-Guérin (BCG) is the most effective intravesical immunotherapy for superficial bladder cancer. Although generally well tolerated, BCG-related infectious complications may occur following instillation. Much of the current knowledge about this complication comes from single case reports, with heterogeneous diagnostic and therapeutic… CONTINUE READING